Dr. Oz has extolled Ozempic’s promise for weight-loss. Now Medicare, which Trump wants Oz to oversee, may cover it.

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

The country sees securing equal access to innovative medicines as its presidency goal in pharma legislative talks.

"Elon Musk is right," the senator tweeted. "The Pentagon, with a budget of $886 billion, just failed its 7th audit in a row.

Even as weight-loss drugs such as Wegovy and Zepbound explode in popularity, many Americans struggle to afford them.

Private insurance companies say U.S. patients aren't paying the true cost of expensive medications such as Wegovy and Zepbound, which can easily cost upwards of $1,000. Wegovy, the weight-loss ...

We recently published a list of 12 Best ADR Stocks To Invest In According to Analysts. In this article, we are going to take ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Macy’s is investigating how hundreds of millions of dollars were hidden by one employee. The retailer delayed its quarterly ...

Whether millions gain access to breakthrough anti-obesity treatments may depend on Kennedy, Mehmet Oz and other key players ...

In fact, Viking just gave investors an update which firms up its status as a very promising company. Here's what it reported, ...

Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...